Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Merck Sharp & Dohme LLC540 enrolled

Overview

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

The duration of treatment is 10 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

540

Conditions

Major Depressive Disorder

Interventions

aprepitantDRUG

Comparator: placebo (unspecified)DRUG

Eligibility

Sex: ALLMin age: 65 Years

Medical Language ↔ Plain English

Patients with Major Depressive Disorder

Outcomes

Primary Outcomes

HAMD-17 score </= 10 after 10 weeks; maintenance of antidepressant effect for 6-10 months; tolerability

Time frame: After 10 weeks & 6-10 months

Secondary Outcomes

CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; MADRS total score change at Month 6, HAMA total score change at Month 6

Time frame: 6 Months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.